Focus Advisor Solutions LLC raised its stake in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 71.0% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 45,488 shares of the biotechnology company’s stock after purchasing an additional 18,885 shares during the period. Focus Advisor Solutions LLC’s holdings in Exelixis were worth $2,657,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Independent Advisor Alliance purchased a new position in shares of Exelixis during the third quarter valued at approximately $217,000. Global Retirement Partners LLC grew its holdings in Exelixis by 164.6% during the third quarter. Global Retirement Partners LLC now owns 27,282 shares of the biotechnology company’s stock worth $1,594,000 after buying an additional 16,972 shares in the last quarter. Edgestream Partners L.P. purchased a new stake in Exelixis in the 3rd quarter valued at $4,344,000. HighTower Advisors LLC raised its position in Exelixis by 8.5% in the 3rd quarter. HighTower Advisors LLC now owns 315,780 shares of the biotechnology company’s stock valued at $18,445,000 after buying an additional 24,618 shares during the last quarter. Finally, Bessemer Group Inc. lifted its stake in Exelixis by 22.1% during the 3rd quarter. Bessemer Group Inc. now owns 2,418 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 437 shares in the last quarter. 85.27% of the stock is owned by institutional investors.
Analysts Set New Price Targets
A number of equities analysts have issued reports on the stock. Wall Street Zen raised shares of Exelixis from a “buy” rating to a “strong-buy” rating in a report on Monday, November 9th. TD Cowen raised their price target on shares of Exelixis from $55.00 to $76.00 and gave the company a “buy” rating in a research report on Friday, October 30th. HC Wainwright boosted their price target on shares of Exelixis from $56.00 to $78.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. Stifel Nicolaus upped their price objective on shares of Exelixis from $47.00 to $51.00 and gave the stock a “hold” rating in a research report on Thursday, August 6th. Finally, Citigroup reiterated a “market outperform” rating on shares of Exelixis in a research note on Monday, October 19th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Exelixis currently has an average rating of “Hold” and an average price target of $58.62.
Exelixis Stock Performance
NASDAQ EXEL opened at $64.63 on Friday. Exelixis, Inc. has a 52-week low of $39.71 and a 52-week high of $73.69. The company has a 50-day simple moving average of $63.20 and a 200 day simple moving average of $52.84. The company has a market capitalization of $15.77 billion, a PE ratio of 19.35, a price-to-earnings-growth ratio of 1.67 and a beta of 0.45.
Exelixis (NASDAQ:EXEL – Get Free Report) last released its earnings results on Thursday, October 29th. The biotechnology company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.89 by $0.05. The firm had revenue of $658.70 million for the quarter, compared to analysts’ expectations of $646.51 million. Exelixis had a net margin of 35.45% and a return on equity of 45.54%. The company’s quarterly revenue was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned $0.78 earnings per share. As a group, analysts forecast that Exelixis, Inc. will post 3.42 EPS for the current fiscal year.
About Exelixis
Exelixis, Inc. is a biotechnology company focused on discovering, developing and commercializing medicines for cancer. Founded in 1994 and headquartered in Alameda, California, the company has built its business around oncology treatments and continues to advance a pipeline of potential cancer therapies. Its principal marketed medicine is cabozantinib, sold in the United States as Cabometyx and Cometriq. Cabometyx is used to treat certain patients with advanced kidney, liver and thyroid cancers, while Cometriq is used for medullary thyroid cancer.
Further Reading
- Five stocks we like better than Exelixis
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
